Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Idorsia highlights positive results from study of DORA in pediatric patients with insomnia

Idorsia (SIX: IDIA) has announced positive top-line results from its Phase 2 dose-finding study evaluating 10, 25, and 50 mg doses of daridorexant—the company’s dual orexin receptor antagonist (DORA)—in pediatric...

March 30, 2026

Developments

FDA grants accelerated approval of Rocket’s KRESLADI for pediatric LAD-I

Rocket Pharmaceuticals (NASDAQ: RCKT) has announced FDA approval of KRESLADI, an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of pediatric patients with severe leukocyte adhesion...

March 27, 2026

Developments

FDA clears Lantern/Starlight’s IND for trial of STAR-001 in pediatric cancer

Lantern Pharma (NASDAQ: LTRN) and its subsidiary, closely held Starlight Therapeutics, have announced FDA clearance of the investigational new drug (IND) application for STAR-001, in a planned Phase 1 pediatric clinical...

March 27, 2026

Developments

Radiopharm doses first patient in Phase 1 prostate cancer study

Radiopharm Theranostics (ASX: RAD) has dosed the first patient in its Phase 1 trial of RAD 402, a monoclonal antibody targeting KLK3 radiolabelled with Terbium 161 for advanced prostate cancer. The study will evaluate...

March 27, 2026

Developments

Profound congratulates Texas Prostate’s 100th TULSA Procedure milestone

Profound Medical (NASDAQ:PROF; TSX:PRN) has announced that Texas Prostate, led by Dr. James Cochran, has achieved its 100th TULSA Procedure performed in Dallas Medical Center’s state-of-the-art MRI suite. “Having...

March 27, 2026

Developments

NextPlat expands reach through collaboration with HealthWarehouse.com

NextPlat (NASDAQ: NXPL; NXPLW) has announced a collaboration with HealthWarehouse.com (OTCQB: HEWA) to enable nationwide fulfillment of prescription and over-the-counter (OTC) products. According to NextPlat, the...

March 26, 2026

Developments

Firefly confirms public-private partnership with DoW

Firefly Neuroscience (NASDAQ: AIFF) has announced a partnership with the Department of War (DoW) to support the assessment and treatment of active-duty U.S. service members and veterans suffering from post-traumatic...

March 26, 2026

Developments

IMUNON’s Phase 2 data shows OS increase in women with advanced ovarian cancer

IMUNON (NASDAQ: IMNN) has announced final clinical data from the completed Phase 2 OVATION 2 clinical trial evaluating IMNN-001 in combination with standard of care neoadjuvant and adjuvant chemotherapy (N/ACT) showing...

March 25, 2026

Developments

Amplia reports more responses and improved OS in pancreatic cancer trial

Amplia Therapeutics (ASX: ATX; OTCQB: INNMF) has announced data from the ongoing ACCENT clinical trial of narmafotinib combined with chemotherapy in advanced pancreatic cancer showing a median overall survival (OS) of...

March 23, 2026

Developments

Bioxytran completes $1.2 million private placement

Bioxytran (OTC: BIXT) has announced that it has completed a private placement financing on March 18, 2026, resulting in gross proceeds of approximately $1.2 million. In connection with the financing, the company issued...

March 20, 2026

Developments

Co-Diagnostics inks agreement to expand distribution across South Asia

Co-Diagnostics (NASDAQ: CODX) has signed an agreement for closely held CoSara Diagnostics—the Indian joint venture between Co-Dx and Ambalal Sarabhai—to significantly expand its commercial and distribution territory...

March 20, 2026

Developments

Immutep reports positive Phase 1 results for IMP761 in autoimmune diseases

Immutep (ASX: IMM; NASDAQ: IMMP) has announced positive Phase 1 results for IMP761, a first-in-class LAG-3 agonist antibody designed to potentially supress pathogenic T cell responses in autoimmune diseases. According...

March 19, 2026

Developments

Niagen increases share repurchase program to $20 million

Niagen Bioscience (NASDAQ: NAGE) has announced that its board of directors has authorized an increase to the company’s previously disclosed share repurchase program, raising the total authorization from $10 million to...

March 19, 2026

Developments

Picard / SynCardia’s Total Artificial Heart enables four-year bridge to transplant

Picard Medical (NYSE American: PMI) has announced that a 29-year-old patient successfully received a donor heart transplant after more than four years of being fully supported by the SynCardia Total Artificial...

March 17, 2026

Developments

Trial finds Profound’s TULSA Procedure significantly improves erectile function and continence vs. robotic radical prostatectomy

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic...

March 16, 2026

Developments

Firefly announces discovery of new brain wave biomarkers for differential diagnosis of ADHD

Firefly Neuroscience (NASDAQ: AIFF) has announced advancements in research using resting EEG/cognitive EEG (ERP) brain scans, collected on its FDA 510(k)-cleared Evoke System, to potentially distinguish among the three...

March 13, 2026

Developments

REGENXBIO reports positive data from Phase 1/2 trial of RGX-202 in DMD

REGENXBIO (NASDAQ: RGNX) has announced new positive interim data from the Phase 1/2 AFFINITY DUCHENNE trial of RGX-202—a potential best-in-class therapy for Duchenne muscular dystrophy (DMD). Trial investigator Carolina...

March 11, 2026

Developments

Clearmind advances recruitment for third cohort of CMND-100 trial at leading sites

Clearmind Medicine (NASDAQ: CMND) has announced the continuation of participant enrollment for the third cohort of its ongoing FDA-approved Phase 1/2a trial evaluating CMND-100, its proprietary non-hallucinogenic MEAI...

March 11, 2026

Developments

bioAffinity initiates longitudinal study for CyPath Lung

bioAffinity Technologies (NASDAQ: BIAF; BIAFW) has initiated a planned large-scale, longitudinal clinical study for CyPath Lung, its noninvasive diagnostic test for the detection of early-stage lung cancer. The 2,000...

March 11, 2026

Developments

ACCP Journal publishes PK studies of Tonix’s TONMYA in fibromyalgia

Tonix Pharmaceuticals (NASDAQ: TNXP) has announced that the American College of Clinical Pharmacology (ACCP) journal Clinical Pharmacology in Drug Development published results from clinical pharmacokinetic (PK) studies...

March 6, 2026

Developments

Volition announces first ever automated Nu.Q Vet Cancer Test

VolitionRx (NYSE American: VNRX) has announced the completion of all validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q Vet Cancer Test with closely held Fujifilm Vet Systems Co...

March 6, 2026

Developments

INOVIO and Akeso collaborate to advance GMB therapy

INOVIO (NASDAQ: INO) and Akeso (HKEX: 9926) have announced a clinical trial collaboration and supply agreement to evaluate INO-5412, INOVIO’s DNA immunotherapy candidate, in combination with cadonilimab...

March 4, 2026

Subscribe